Literature DB >> 11160290

Ly-49W, an activating receptor of nonobese diabetic mice with close homology to the inhibitory receptor Ly-49G, recognizes H-2D(k) and H-2D(d).

E T Silver1, D Gong, B Hazes, K P Kane.   

Abstract

The diversity and ligand specificity of activating Ly-49 receptors expressed by murine NK cells are largely unknown. We cloned a new Ly-49-activating receptor, expressed by NK cells of the nonobese diabetic mouse strain, which we have designated Ly-49W. Ly-49W is highly related to the known inhibitory receptor Ly-49G in its carbohydrate recognition domain, exhibiting 97.6% amino acid identity in this region. We demonstrate that the 4D11 and Cwy-3 Abs, thought to be Ly-49G specific, also recognize Ly-49W. Rat RNK-16 cells transfected with Ly-49W mediated reverse Ab-dependent cellular cytotoxicity of FcR-positive target cells, indicating that Ly-49W can activate NK-mediated lysis. We further show that Ly-49W is allo-MHC specific: Ly-49W transfectants of RNK-16 only lysed Con A blasts expressing H-2(k) or H-2(d) haplotypes, and Ab-blocking experiments indicated that H-2D(k) and D(d) are ligands for Ly-49W. Ly-49W is the first activating Ly-49 receptor demonstrated to recognize an H-2(k) class I product. Ly-49G and Ly-49W represent a new pair of NK receptors with very similar ligand-binding domains, but opposite signaling functions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160290     DOI: 10.4049/jimmunol.166.4.2333

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Receptor/ligand avidity determines the capacity of Ly49 inhibitory receptors to interfere with T-cell receptor-mediated activation.

Authors:  Anick Chalifour; Joanne Roger; Suzanne Lemieux; Pascale Duplay
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

2.  The activating Ly49W and inhibitory Ly49G NK cell receptors display similar affinities for identical MHC class I ligands.

Authors:  Brian J Ma; Carla M Craveiro Salvado; Kevin P Kane
Journal:  Immunogenetics       Date:  2014-05-07       Impact factor: 2.846

3.  Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection.

Authors:  Marie-Pierre Desrosiers; Agnieszka Kielczewska; J-C Loredo-Osti; Sonia Girard Adam; Andrew P Makrigiannis; Suzanne Lemieux; Trung Pham; Melissa B Lodoen; Kenneth Morgan; Lewis L Lanier; Silvia M Vidal
Journal:  Nat Genet       Date:  2005-05-15       Impact factor: 38.330

4.  Ly49 cluster sequence analysis in a mouse model of diabetes: an expanded repertoire of activating receptors in the NOD genome.

Authors:  S Belanger; L-H Tai; S K Anderson; A P Makrigiannis
Journal:  Genes Immun       Date:  2008-06-05       Impact factor: 2.676

Review 5.  DAP10- and DAP12-associated receptors in innate immunity.

Authors:  Lewis L Lanier
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

6.  Distinct MHC class I-dependent NK cell-activating receptors control cytomegalovirus infection in different mouse strains.

Authors:  Michał Pyzik; Benoit Charbonneau; Eve-Marie Gendron-Pontbriand; Marina Babić; Astrid Krmpotić; Stipan Jonjić; Silvia M Vidal
Journal:  J Exp Med       Date:  2011-04-25       Impact factor: 14.307

7.  Identities of P2 and P3 Residues of H-2Kb-Bound Peptides Determine Mouse Ly49C Recognition.

Authors:  Elsa A Marquez; Kevin P Kane
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

Review 8.  Ly49 receptors: innate and adaptive immune paradigms.

Authors:  Mir Munir A Rahim; Megan M Tu; Ahmad Bakur Mahmoud; Andrew Wight; Elias Abou-Samra; Patricia D A Lima; Andrew P Makrigiannis
Journal:  Front Immunol       Date:  2014-04-02       Impact factor: 7.561

Review 9.  The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.

Authors:  Sourav Paul; Girdhari Lal
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.